Is Thorazine (chlorpromazine) appropriate for treating anxiety and suicidal thoughts?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Thorazine (Chlorpromazine) is NOT Appropriate for Treating Anxiety and Suicidal Thoughts

Chlorpromazine should not be used as a treatment for anxiety or suicidal ideation in modern clinical practice. While this first-generation antipsychotic has sedating properties, there are far safer and more effective evidence-based alternatives available, and its use carries significant risks without proven benefit for these indications.

Why Chlorpromazine is Inappropriate

For Anxiety Disorders

The 2020 AACAP guidelines for anxiety disorders in children and adolescents 1 clearly establish SSRIs as first-line pharmacotherapy for anxiety, with strong evidence for efficacy and tolerability. Chlorpromazine is not mentioned as a treatment option for primary anxiety disorders.

While older research from 1982 showed chlorpromazine could abolish anticipatory anxiety responses in experimental settings 2, and a 2006 review suggested low-dose trifluoperazine (a different typical antipsychotic) showed some efficacy in GAD 3, there are no well-designed modern studies supporting chlorpromazine for anxiety treatment. The evidence base is limited to small, poorly designed older trials.

For Suicidal Thoughts

The 2025 VA/DoD guidelines on suicide risk management 4 do not recommend chlorpromazine for suicidal ideation. The guideline suggests:

  • Clozapine (weak for) for patients with schizophrenia/schizoaffective disorder and suicidal ideation or history of attempts 4
  • Ketamine infusion (weak for) as adjunctive treatment for short-term reduction in suicidal ideation in major depressive disorder 4

The WHO 2011 guidelines explicitly state that chlorpromazine should NOT be used for behavioral symptoms in dementia 5, citing safety concerns. While this addresses a different population, it reflects the medication's unfavorable risk-benefit profile.

Significant Safety Concerns

The FDA label for chlorpromazine 6 highlights multiple serious risks:

Cardiovascular Risks

  • Orthostatic hypotension (sedating, anticholinergic effects)
  • QTc prolongation
  • Parenteral use may cause local irritation
  • Falls risk due to somnolence and postural hypotension 6

Neurological Risks

  • Extrapyramidal symptoms (EPSEs)
  • Neuroleptic Malignant Syndrome (NMS) - potentially fatal
  • Tardive dyskinesia with chronic use
  • Lowers seizure threshold 6

Hematologic Risks

  • Leukopenia, neutropenia, and agranulocytosis requiring CBC monitoring 6

Other Concerns

  • Anticholinergic effects (problematic in elderly, those with glaucoma)
  • May impair mental/physical abilities
  • Prolactin elevation
  • Hepatotoxicity risk 6

What Should Be Used Instead

For Anxiety

SSRIs are the evidence-based first-line treatment 1:

  • Fluoxetine, sertraline, paroxetine, fluvoxamine, or citalopram
  • Start low, titrate slowly over 6-12 weeks
  • Monitor for suicidal thinking (boxed warning through age 24)
  • Generally well-tolerated with manageable side effects

For Suicidal Ideation

The approach depends on underlying diagnosis:

If schizophrenia/schizoaffective disorder present:

  • Consider clozapine (the only antipsychotic with evidence for reducing suicide risk) 4, 7

If major depressive disorder:

  • SSRIs or other second-generation antidepressants as first-line 8
  • Consider ketamine infusion for acute suicidal ideation 4
  • Monitor closely, especially in first 1-2 months 8

Non-pharmacologic interventions are essential:

  • Cognitive behavioral therapy focused on suicide prevention (strong recommendation) 4
  • Safety planning and crisis response planning
  • Restrict access to lethal means 5
  • Periodic caring communications following hospitalization 4

Limited Context Where Chlorpromazine Appears

The only modern guideline mentioning chlorpromazine is the 2018 ESMO delirium guidelines 9, which list it as an option for delirium management in cancer patients at doses of 12.5-25 mg PO/PR, with cautions about sedation, EPSEs, orthostatic hypotension, and QTc prolongation. This is a completely different clinical context than anxiety or suicidal thoughts.

Clinical Bottom Line

Do not use chlorpromazine for anxiety or suicidal ideation. The risk-benefit ratio is unfavorable when evidence-based alternatives (SSRIs for anxiety, clozapine for suicidal ideation in psychotic disorders, CBT-based psychotherapy) exist with superior efficacy and safety profiles. If a patient is currently on chlorpromazine for these indications, strongly consider transitioning to appropriate evidence-based treatment with psychiatric consultation.

References

1
Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

7
Research

Prevention of suicide by clozapine in mental disorders: systematic review.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2023

Related Questions

Can Thorazine (chlorpromazine) be prescribed off-label for anxiety?
How to manage anxiety in a patient taking antipsychotics?
What are the recommended dosing guidelines for chlorpromazine (including oral and intramuscular routes) for adults, children, adolescents, and elderly patients, and how should the dose be adjusted in patients with hepatic or renal impairment?
What is the appropriate management for chlorpromazine toxicity?
In an 83‑year‑old female nursing‑home resident with dementia, traumatic brain injury, multiple cerebrovascular accidents, delusional disorder, obsessive‑compulsive behavior, generalized anxiety disorder, primary insomnia, and paranoid personality disorder who is currently on a clonazepam taper (0.75 mg total per day), venlafaxine 37.5 mg daily, quetiapine (Seroquel) 25 mg at bedtime, and lamotrigine 200 mg daily, and now presents with cognitive decline, hypervigilance, obsessive‑compulsive behaviors, and anxiety, what are the best psychotropic medication options?
According to guidelines, how long is an imaging order valid?
For an infant weighing 5.4 kg, what is the appropriate intravenous infusion rate?
How should I manage a patient with positive antinuclear antibody, elevated liver enzymes, high ceruloplasmin, and increased copper levels?
Can I crush clonidine tablets?
Does radiation to the lung cause a reduction in forced vital capacity (FVC)?
What is the appropriate dose and duration of cephalexin 500 mg for an adult with an eye hordeolum?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.